阿尼卡医疗公司近日明确表示,其创新产品Cingal与Hyalofast将继续作为公司至2026年的核心战略发展重点。当前,公司正全力推进这两款产品未来在美国市场的上市筹备工作,旨在通过强化产品管线布局,为长期增长奠定坚实基础。
阿尼卡医疗公司近日明确表示,其创新产品Cingal与Hyalofast将继续作为公司至2026年的核心战略发展重点。当前,公司正全力推进这两款产品未来在美国市场的上市筹备工作,旨在通过强化产品管线布局,为长期增长奠定坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.